| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
25010 |
| Drug |
Durvalumab |
| Brand |
Imfinzi® |
| Indication |
Durvalumab (Imfinzi®) is indicated as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy. |
| Rapid review commissioned |
14/02/2025 |
| Rapid review completed |
06/03/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of durvalumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
27/03/2025 |
| Pre-submission consultation with Applicant |
14/05/2025 |
| Full submission received from Applicant |
10/09/2025 |
